Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...
The current coronavirus disease 2019 (COVID-19) pandemic, which is due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 5.5 million casualties to date. Despite ...
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare ...
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market ...
Zacks Investment Research on MSN
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
Novartis NVS recently announced positive final results from the late-stage, APPLAUSE-IgAN, study on Fabhalta (iptacopan) in ...
Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback